Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OASIS-2: mirikizumab versus secukinumab and placebo in moderate to severe plaque psoriasis
MOH_2018-07-30_002381Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mirikizumab in plaque psoriasis (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: High-level clinical response of mirikizumab versus placebo during induction and High-level clinical response of mirikizumab versus secukinumab during induction. Started Apr 2018; status: completed.
02
Drugs
mirikizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on MOH_2018-07-30_002381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-07-30_002381.